Remicade: Biosimilars And Pricing Pressure Wear On J&J's Blockbuster Brand
US sales were down 14%, but much of the hit was due to a 2016 price adjustment that was felt across the pharma portfolio, and execs insisted the impact of biosimilars is more moderate than expected.
You may also be interested in...
FDA approved Johnson & Johnson's IL-23 blocker guselkumab July 13; the drug will be priced at an annual wholesale acquisition cost of $58,100, roughly in line with the currently marketed IL-17 blocker Cosentyx.
The diversified pharma has two NMEs and three sNDAs pending at FDA in immunology, as well as six more anticipated sNDA filings. Immunology Therapeutic Head Susan Dillon told investors why there is still plenty of opportunity for growth in key autoimmune diseases.
Infliximab-abda gains FDA licensure without having faced an advisory committee review; under current case law, launch could come as early as mid-October.